Avecho Biotechnology Ltd
ASX:AVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avecho Biotechnology Ltd
Selling, General & Administrative
Avecho Biotechnology Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avecho Biotechnology Ltd
ASX:AVE
|
Selling, General & Administrative
-AU$2.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
14%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Selling, General & Administrative
-AU$20.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Selling, General & Administrative
-AU$192.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Selling, General & Administrative
-AU$6.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-7%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Selling, General & Administrative
-AU$11.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Selling, General & Administrative
-AU$41.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
Avecho Biotechnology Ltd
Glance View
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
See Also
What is Avecho Biotechnology Ltd's Selling, General & Administrative?
Selling, General & Administrative
-2.4m
AUD
Based on the financial report for Dec 31, 2025, Avecho Biotechnology Ltd's Selling, General & Administrative amounts to -2.4m AUD.
What is Avecho Biotechnology Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
14%
Over the last year, the Selling, General & Administrative growth was -29%. The average annual Selling, General & Administrative growth rates for Avecho Biotechnology Ltd have been -6% over the past three years , -2% over the past five years , and 14% over the past ten years .
